Sign in
Active, not recruitingNo phase

PERSEVERE- A Trial to Evaluate AMDS in Acute DeBakey Type I Dissection

Key facts

Who runs it
Artivion Inc.
Where
Ann Arbor, Atlanta, Aurora, Austin, Birmingham, Boston, Charleston, Charlotte, Chicago, Cleveland, Gainesville, Hartford, Houston, Los Angeles, New York, Palo Alto, Philadelphia, Pittsburgh, Plano, Portland, St Louis, The Bronx, and Wynnewood, United StatesSee the 25 sites
Trial code
Status
Active, not recruiting
People taking part
115 people enrolled
Started
27 May 2022
Expected to end
6 Dec 2029
Type of study
Interventional
Treatments tested
  • AMDS
Record updated
15 January 2025

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 35 criteriaShow less

Who can take part

  • ≥18 years of age or ≤80 years of age (male or female) at time of surgery
  • Acute DeBakey type I dissection based on computed tomography angiography (CTA) and diagnosed ≤14 days from of the index event
  • Presence of malperfusion (cerebral, visceral, renal, spinal cord, and/or peripheral)

Who cannot take part

  • Previous placement of a thoracic endovascular graft
  • Interventional and/or open surgical procedures 30 days prior to the dissection repair
  • Planned major interventional and/or open surgical procedures 30 days post the dissection repair
  • Diagnosed with acute myocardial infarction in the 30 days prior to the dissection diagnosis
  • Diagnosed with severe and catastrophic neurological complications in the 30 days prior to the dissection diagnosis (namely, obtundation or coma)
  • Clinical or radiographic signs of bowel infarction or gastrointestinal hemorrhage
  • Systemic infection
  • Uncontrollable anaphylaxis to iodinated contrast (patients with allergy to iodinated contrast but not anaphylaxis may be eligible with appropriate pre-medication, as deemed suitable by the Investigator)
  • Known allergy(ies) to nitinol and/or polytetrafluoroethylene
  • History of bleeding disorder (i.e. hemophilia)
  • Suspicion of bowel necrosis (as determined by the implanting physician based on imaging observations, peritoneal signs, surgical exploration, elevated serum lactate levels, low pH, and/or acidosis)
  • Base deficit > -10 mmol/L or -10 mEq/L
  • Previously diagnosed with Marfan syndrome, Ehlers-Danlos syndrome, or Loeys-Dietz syndrome based on laboratory genetic testing
  • Current Stage 5 end stage chronic kidney disease (eGFR ≤ 15 mL/min)
  • Other medical condition that is associated with limited life expectancy <2 years (e.g., cancer, congestive heart failure)
  • Pregnant or breastfeeding
  • Unwilling to comply with the follow-up schedule
  • Institutionalized due to administrative or judicial order
  • Unwilling to accept blood transfusions for any reason
  • Coronary malperfusion
  • In circulatory shock (i.e., systolic blood pressure <90 mmHg) at time of screening
  • In extreme hemodynamic compromise requiring cardiopulmonary resuscitation at time of screening
  • American Society of Anesthesiologists risk class V (i.e., moribund patient not expected to live 24 hours with or without operation) or class VI (a declared brain dead patient whose organs are being removed for donor purposes)
  • Inability to obtain CT angiograms for follow-up
  • A primary entry tear that extends into the arch or distal to the left subclavian artery
  • Need for a total aortic arch replacement and/or repair, or reconstruction, of any part of the arch, and branch vessels (including extra-anatomic bypass of the branch vessels), for any reason as deemed necessary by the Investigator
  • Any pathology of mycotic origin
  • Aortic fistulous communication with non-vascular structure (e.g., esophagus, bronchial)
  • Extensive thrombus or calcifications in the aortic arch, as defined by CTA
  • Excessive tortuosity precluding safe passage of the AMDS, as defined by CTA
  • Descending thoracic aneurysm involving the proximal third (one-third) of the descending aorta and measuring >45 mm in diameter
  • Aortic arch aneurysm >50 mm in diameter

Where in United States

  • University of MichiganAnn Arbor, United States
  • Emory University Medical CenterAtlanta, United States
  • University of ColoradoAurora, United States
  • Ascension Seton/University of TexasAustin, United States
  • University of Alabama at BirminghamBirmingham, United States
  • Massachusetts General HospitalBoston, United States
  • Medical University of South CarolinaCharleston, United States
  • Atrium Health - Carolinas Medical CenterCharlotte, United States
  • Northwestern UniversityChicago, United States
  • Cleveland Clinic FoundationCleveland, United States
  • University of FloridaGainesville, United States
  • Hartford HospitalHartford, United States
  • Baylor College of Medicine St. Luke's Medical CenterHouston, United States
  • University of Southern CaliforniaLos Angeles, United States
  • Columbia University Irving Medical Center/New York Presbyterian HospitalNew York, United States
  • Mount Sinai HospitalNew York, United States
  • NorthwellNew York, United States
  • Stanford UniversityPalo Alto, United States
  • University of PennsylvaniaPhiladelphia, United States
  • University of Pittsburgh Medical CenterPittsburgh, United States
  • Baylor Scott & White The Heart Hospital - PlanoPlano, United States
  • Oregon Health and Science UniversityPortland, United States
  • Washington University in St. LouisSt Louis, United States
  • Montefiore Einstein MedicalThe Bronx, United States
  • Lankenau Medical CenterWynnewood, United States

About the trial

What the trial wants to find out

Prospective, non-randomized, multicenter clinical investigation to assess the safety and effectiveness of AMDS in the treatment of patients with acute DeBakey type I dissection, with evidence of malperfusion, through open surgical repair.

The group in the trial

  • Acute DeBakey Type I DissectionTreatment being tested

    In eligible patients, the ascending aorta is transected and removed in a routine standard of care manner utilizing hypothermic circulatory arrest; the operator will leave at least 10 mm (1.0 cm) aortic tissue proximal to the innominate artery. AMDS is pre-loaded onto the delivery system and is delivered into the true lumen through the open distal aorta and implanted according to the instructions for use.

    Treatment: AMDS

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A ProspEctive, Single ARm, Multi-center Clinical InveStigation to EValuatE the Safety and Effectiveness of AMDS in the TREatment of Acute DeBakey Type I Dissection: PERSEVERE
Publications
Record updated
15 January 2025